| Drug Name | AOX-084 |
| Description |
AOX-084 is a replication-competent oncolytic herpes-simplex-virus type 1 (HSV-1) encoding a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The candidate is in phase II clinical development in untreated patients with solid tumors. |
| Target | CSF2 |
| Drug Modality | Oncolytic Virus |
| Indication | Solid Tumor |
| Product Category | Cancer Immunotherapy |
| Mechanism of Action | Directly Mediating Tumor Lysis and Enhancing the Activity of Immune Response |
| Status | Phase II |
| Patent | Granted |
Protheragen Inc. is actively seeking partnership for AOX-084. Potential collaboration can be strategic alliance, licensing, or marketing agreement.
We look forward to hearing from you.
The protein encoded by this gene is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The active form of the protein is found extracellularly as a homodimer. This gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13. This gene plays a role in promoting tissue inflammation.
Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant. Different types of solid tumors are named for the type of cells that form them, such as breast cancer. Based on projections, cancer deaths will continue to rise with an estimated 11.4 million people dying from cancer in 2030.
The best strategy for fighting cancer is prevention to reduce cancer risk. Nevertheless, even if we were to apply all that we know about preventing cancer, one out of four cancers would still occur. Because of this, therapies that target malignancies after they have developed will continue to be important for some time to come. The most commonly used treatment modalities of cancer include some combination of surgery, radiation therapy, and chemotherapy. The best approach to treating cancer provides a balance between therapeutic effectiveness and minimization of treatment-associated side effects.
The global market for solid tumor treatment was estimated at $121.3 billion in 2018 and is expected to reach $424.6 billion by 2027, expanding at a CAGR of 15% from 2019 to 2027.
| Molecular Mechanism | Lysing tumor cells and enhancing T cell activity |
The international patent applications under the PCT have been granted.
| Discovery/Optimization | Preclinical | Clinical | ||
| AOX-084 |  |
|||
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |